Journal of Infectious Diseases最新文献_第10页

Trends in commercial laboratory testing and positivity for Bordetella species in the United States, 2019 through 2023. 2019年至2023年美国商业实验室检测和博德特拉菌阳性趋势。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-21 DOI: 10.1093/infdis/jiaf141

Cheryl J Isenhour, Lucia Pawloski, Susan Hariri, Tami H Skoff

{"title":"Trends in commercial laboratory testing and positivity for Bordetella species in the United States, 2019 through 2023.","authors":"Cheryl J Isenhour, Lucia Pawloski, Susan Hariri, Tami H Skoff","doi":"10.1093/infdis/jiaf141","DOIUrl":"https://doi.org/10.1093/infdis/jiaf141","url":null,"abstract":"Background: Diagnostic methods for detecting infections caused by Bordetella species include culture, polymerase chain reaction (PCR), and serology. As the epidemiology of pertussis continues to evolve in the United States, we aimed to assess recent trends in provider testing practices and positivity for both B. pertussis and B. parapertussis.Methods: Using deidentified data from a large U.S. commercial laboratory, we identified Bordetella tests from 2019 through 2023. We described monthly trends in number of tests ordered by test type for culture, PCR (both non-panel B. pertussis and B. parapertussis tests and those included as part of a respiratory panel), and serology, as well as percent positivity for serology and PCR. We also examined orders and positivity by patient age group and geographic region of the ordering provider.Results: Among 527,206 tests, we identified 316,428 (60.1%) PCR tests, 204,480 (38.8%) serologic tests, and 5,840 (1.1%) cultures. While most PCR tests were ordered as part of a respiratory panel (83.5%), only 215 (0.08%) were positive for B. pertussis. Non-panel PCR positivity for B. pertussis was substantially higher but variable over the study period, ranging from 3% to 16%. We also observed a notable increase in B. parapertussis positivity on non-panel PCR tests in the first half of 2023.Conclusions: Both PCR and serology remain preferred diagnostic methods for providers. Despite their increasing popularity, B. pertussis positivity remained low for respiratory panels. Data from commercial laboratories can provide crucial insights into pertussis diagnostic trends over time.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eighteen Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media during the Pneumococcal Conjugate Vaccine Era, 2006-2023. 肺炎球菌结合疫苗时代（2006-2023）对单纯和复杂急性中耳炎18年的纵向研究

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-20 DOI: 10.1093/infdis/jiaf154

Naoko Fuji, Frank N Salamone, Ravinder Kaur, Peter Bajorski, Eduardo Gonzalez, Liz Wang, Mohammad Ali, Ashley Miller, Lindsay R Grant, Adriano Arguedas, Michael Pichichero

{"title":"Eighteen Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media during the Pneumococcal Conjugate Vaccine Era, 2006-2023.","authors":"Naoko Fuji, Frank N Salamone, Ravinder Kaur, Peter Bajorski, Eduardo Gonzalez, Liz Wang, Mohammad Ali, Ashley Miller, Lindsay R Grant, Adriano Arguedas, Michael Pichichero","doi":"10.1093/infdis/jiaf154","DOIUrl":"https://doi.org/10.1093/infdis/jiaf154","url":null,"abstract":"Background: We analyzed the demographic and risk factors, middle ear fluid (MEF) pathogens, pneumococcus serotype distribution, and bacterial antibiotic non-susceptibility among children with uncomplicated acute otitis media (uAOM) and complex AOM (cAOM) over three timeframes: 2006-2009 (PCV7 era), 2010-2014 (early-PCV13 era), and 2015-2023 (late-PCV13 era).Methods: 1,537 children were enrolled over 18 years and prospectively followed from 6-36 months of age. Upon diagnosis of AOM, tympanocentesis was performed for MEF collection and culture. Electronic medical records were analyzed to identify uAOM and cAOM episodes.Results: Analysis of demographic data showed that male sex, family history of AOM, and daycare attendance increased the odds of developing cAOM compared to uAOM. Streptococcus pneumoniae was less likely in cAOM, and Haemophilus influenzae more likely as compared to uAOM. AOM caused by S. pneumoniae decreased significantly in the early-PCV13 and late-PCV13 eras. This was driven by decreases in cAOM caused by PCV13 S. pneumoniae strains, especially serotype 19A. S. pneumoniae penicillin non-susceptibility was associated with cAOM and reduced in the early-PCV13 era.Discussion: The risk factors for developing cAOM compared to uAOM are similar. PCV13 significantly reduced cAOM and penicillin non-susceptibility associated with S. pneumoniae, driven by reduction in cases caused by serotype 19A. H. influenzae continued to be a dominant cause of cAOM. Although non-PCV13 S. pneumoniae serotypes emerged in the late-PCV13 era, the lower level of cAOM caused by S. pneumoniae was sustained.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case-Control Study of Cervicovaginal β/γ-Human Papillomavirus Infection in Women With Human Immunodeficiency Virus and Its Relation to Incident Cervical Precancer. 艾滋病女性宫颈阴道 Beta-/Gamma-HPV 感染及其与宫颈癌前病变关系的病例对照研究。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae588

Howard D Strickler, Mykhaylo Usyk, Isam-Eldin Eltoum, Natalie Bachman, Nancy A Hessol, Lisa Flowers, Lisa Rahangdale, Jessica M Atrio, Catalina Ramirez, Howard Minkoff, Adaora A Adimora, Igho Ofotokun, Marla J Keller, Margaret Fischl, Sadeep Shrestha, Rodney Wright, Gypsyamber D'Souza, Lorraine Sanchez-Keeland, Xianhong Xie, Xiaonan Xue, Kathryn Anastos, L Stewart Massad, Joel M Palefsky, Robert D Burk

{"title":"Case-Control Study of Cervicovaginal β/γ-Human Papillomavirus Infection in Women With Human Immunodeficiency Virus and Its Relation to Incident Cervical Precancer.","authors":"Howard D Strickler, Mykhaylo Usyk, Isam-Eldin Eltoum, Natalie Bachman, Nancy A Hessol, Lisa Flowers, Lisa Rahangdale, Jessica M Atrio, Catalina Ramirez, Howard Minkoff, Adaora A Adimora, Igho Ofotokun, Marla J Keller, Margaret Fischl, Sadeep Shrestha, Rodney Wright, Gypsyamber D'Souza, Lorraine Sanchez-Keeland, Xianhong Xie, Xiaonan Xue, Kathryn Anastos, L Stewart Massad, Joel M Palefsky, Robert D Burk","doi":"10.1093/infdis/jiae588","DOIUrl":"10.1093/infdis/jiae588","url":null,"abstract":"We studied cervicovaginal β/γ-human papillomavirus (HPV) and their relationship to cervical precancer in women with human immunodeficiency virus; having previously reported strong positive associations of β/γ-HPV with incident head and neck cancer in the general population. Case patients (n = 124) had cervical intraepithelial neoplasia (CIN) 3 or 2. Controls (n = 247) were individually matched 2:1 to case patients. Unexpectedly, multivariate analyses found strong inverse associations between β/γ-HPV and CIN-2/3 (odds ratio, 0.19 [95% confidence interval, .04-.86]; P = .03; Ptrend < .01]). This is, to our knowledge, the first study of β/γ-HPV and cervical precancer. If confirmed, a strong inverse (protective) association would be of potential clinical and biologic relevance.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"595-599"},"PeriodicalIF":5.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction and replacement of: Commentary: Mendelian Randomization for Causal Inference. 撤回和替换：评论：孟德尔随机化的因果推论。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae358

引用次数: 0

Correction to: An Update on Highly Pathogenic Avian Influenza A(H5N1) Virus, Clade 2.3.4.4b. 更正：关于高致病性禽流感A（H5N1）病毒，进化分支2.3.4.4b的最新情况。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiaf085

引用次数: 0

Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. 多罗替韦加拉米夫定作为一线抗逆转录病毒治疗对外周血中 HIV-1 储库和炎症标记物的影响

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae530

Lucía Bailón, Maria C Puertas, Maria C García-Guerrero, Igor Moraes-Cardoso, Ester Aparicio, Yovaninna Alarcón-Soto, Angel Rivero, Elias P Rosen, Jacob D Estes, Julià Blanco, Alex Olvera, Beatriz Mothe, Javier Martinez-Picado, José Moltó

{"title":"Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.","authors":"Lucía Bailón, Maria C Puertas, Maria C García-Guerrero, Igor Moraes-Cardoso, Ester Aparicio, Yovaninna Alarcón-Soto, Angel Rivero, Elias P Rosen, Jacob D Estes, Julià Blanco, Alex Olvera, Beatriz Mothe, Javier Martinez-Picado, José Moltó","doi":"10.1093/infdis/jiae530","DOIUrl":"10.1093/infdis/jiae530","url":null,"abstract":"Background: To compare the effects of first-line antiretroviral therapy (ART) with dolutegravir plus lamivudine (DTG + 3TC) versus dolutegravir plus emtricitabine/tenofovir alafenamide (DTG + FTC/TAF) on the human immunodeficiency virus type 1 (HIV-1) reservoir and immune activation biomarkers in people with HIV (PWH).Methods: DUALITY was a 48-week, single-center, randomized, open-label clinical trial in ART-naive PWH, randomized (1:1) to receive ART with DTG + 3TC (2DR group) or DTG + FTC/TAF (3DR group). We measured total and intact proviral HIV-1 DNA, cell-associated RNA in CD4+ T cells, frequency of HIV-infected CD4+ T cells able to produce p24, plasma soluble inflammatory markers, and activation and exhaustion markers in CD4+ and CD8+ T cells.Results: Forty-four participants (22 per study arm) were enrolled, with baseline mean (standard deviation) log10 plasma viral load (pVL) 4.4 (0.7) copies/mL and CD4+ T-cell counts of 493 (221) cells/μL. At week 48, all participants had pVL <50 copies/mL at week 48, except for 1 participant in the 2DR group who was resuppressed after treating syphilis. Changes from baseline in reservoir parameters and immune biomarkers were comparable between groups.Conclusions: First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC/TAF, supporting DTG/3TC among preferred first-line ART options for PWH.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"600-610"},"PeriodicalIF":5.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination. 更正：妊娠期内接种破伤风、白喉和无细胞百日咳疫苗后（早产儿）体内百日咳特异性母体抗体的半衰期估计。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae565

引用次数: 0

Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023. 2018-2023 年在美国三个城市性健康诊所就诊的 18-45 岁男男性行为者接种肛门 HPV 疫苗的有效性。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae394

Carla L DeSisto, Rachel L Winer, Troy D Querec, Damilola Dada, Preeti Pathela, Lenore Asbel, John Lin, Jennifer Tang, Alfred Iqbal, Elissa Meites, Elizabeth R Unger, Lauri E Markowitz

{"title":"Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023.","authors":"Carla L DeSisto, Rachel L Winer, Troy D Querec, Damilola Dada, Preeti Pathela, Lenore Asbel, John Lin, Jennifer Tang, Alfred Iqbal, Elissa Meites, Elizabeth R Unger, Lauri E Markowitz","doi":"10.1093/infdis/jiae394","DOIUrl":"10.1093/infdis/jiae394","url":null,"abstract":"Background: We assessed human papillomavirus (HPV) vaccine effectiveness (VE) against anal HPV among men who have sex with men (MSM) in 2018-2023.Methods: Residual anal specimens from MSM without HIV aged 18-45 years were tested for HPV. We calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for associations between vaccination (≥1 dose) and quadrivalent vaccine (4vHPV)-type prevalence adjusting for city, race/ethnicity, and nonvaccine-type HPV prevalence, stratified by age group (18-26, 27-45 years). VE was calculated as (1 - aPR) × 100.Results: Among 2802 persons aged 18-26, 4vHPV-type prevalence was lower in those vaccinated at age <18 (aPR = 0.13; 95% CI, .08-.22; VE = 87%) and those vaccinated ≥2 years before specimen collection (aPR = 0.52; 95% CI, .42-.64; VE = 48%) compared with unvaccinated persons. Among 3548 persons aged 27-45, 4vHPV-type prevalence was lower in those vaccinated at ages 18-26 (aPR = 0.68; 95% CI, .57-.82; VE = 32%) and those vaccinated ≥2 years before specimen collection (aPR = 0.66; 95% CI, .57-.77; VE = 33%) compared with unvaccinated persons. While we observed no VE in persons vaccinated at age >26 overall, 4vHPV-type prevalence was lower in the subgroup vaccinated ≥2 years before specimen collection (aPR = 0.71; 95% CI, .56-.89; VE = 29%).Conclusions: We found high VE against anal 4vHPV-type prevalence among MSM aged 18-26 who were vaccinated at age <18. Lower VE was observed among MSM aged 27-45 who were vaccinated at age 18-26 or ≥2 years before specimen collection. While ideally vaccination should be given at younger ages, vaccination can prevent some future infections in this population.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"751-761"},"PeriodicalIF":5.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study. XBB.1.5单价疫苗在2019冠状病毒病流行时代的自然增强和免疫原性：一项纵向观察研究。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiaf073

引用次数: 0

Impact of Multicohort Human Papillomavirus Vaccination on Cervical Cancer in Women Below 30 Years of Age: Lessons Learned From the Scandinavian Countries. 多队列 HPV 疫苗接种对 30 岁以下女性宫颈癌的影响：斯堪的纳维亚国家的经验教训。

IF 5 2区医学

Journal of Infectious Diseases Pub Date : 2025-03-17 DOI: 10.1093/infdis/jiae584

Ståle Nygård, Thea Eline Hetland Falkenthal, Tina Sture, Elsebeth Lynge, Miriam Elfström, Mari Nygård

引用次数: 0